Scientific article
OA Policy
English

Impairment of hippocampal astrocyte-mediated striatal dopamine release and locomotion in Alzheimer's disease

Published inNeuroImage, vol. 298, 120778
Publication date2024-09
First online date2024-08-07
Abstract

Background: Clinical and translational research has identified deficits in the dopaminergic neurotransmission in the striatum in Alzheimer's disease (AD) and this could be related to the pathophysiology of psychiatric symptoms appearing even at early stages of the pathology.

Hypothesis: We hypothesized that AD pathology in the hippocampus may influence dopaminergic neurotransmission even in the absence of AD-related lesion in the mesostriatal circuit.

Methods: We chemogenetically manipulated the activity of hippocampal neurons and astrocytes in wild-type and hemizygous TgF344-AD (Tg) rats, an animal model of AD pathology. We assessed the brain-wide functional output of this manipulation using in vivo Single Photon Emission Computed Tomography to measure cerebral blood flow and D2/3 receptor binding, in response to acute (3mg/kg i.p.) and chronic (0.015 mg/ml in drinking water, 28 days) stimulation of neurons or astrocytes with clozapine N-oxide. We also assessed the effects of the chronic chemogenetic manipulations on D2 receptor density, low or high aggregated forms of amyloid Aβ40 and Aβ42, astrocytes and microglial reactivity, and the capacity of astrocytes and microglia to surround and phagocytize Aβ both locally and in the striatum.

Results: We showed that acute and chronic neuronal and astrocytic stimulation induces widespread effects on the brain regional activation pattern, notably with an inhibition of striatal activation. In the Tg rats, both these effects were blunted. Chemogenetic stimulation in the hippocampus increased microglial density and its capacity to limit AD pathology, whereas these effects were absent in the striatum perhaps as a consequence of the altered connectivity between the hippocampus and the striatum.

Conclusions: Our work suggests that hippocampal AD pathology may alter mesostriatal signalling and induce widespread alterations of brain activity. Neuronal and astrocytic activation may induce a protective, Aβ-limiting phenotype of microglia, which surrounds Aβ plaques and limits Αβ concentration more efficiently.

Keywords
  • AAV vector gene therapy
  • Alzheimer's disease
  • Astrocytes
  • Brain activity
  • Dopamine
  • TgF344-AD
Citation (ISO format)
TOURNIER, Benjamin et al. Impairment of hippocampal astrocyte-mediated striatal dopamine release and locomotion in Alzheimer’s disease. In: NeuroImage, 2024, vol. 298, p. 120778. doi: 10.1016/j.neuroimage.2024.120778
Main files (1)
Article (Published version)
Secondary files (1)
Supplemental data
accessLevelPublic
Identifiers
Journal ISSN1053-8119
145views
103downloads

Technical informations

Creation09/08/2024 11:27:00
First validation03/09/2024 09:11:30
Update13/10/2025 12:47:08
Status update03/09/2024 09:11:30
Last indexation03/11/2025 16:26:29
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack